Mitsubishi Tanabe to pay $1.1bn for Parkinson's drug formulator Neuroderm

By Gareth Macdonald

- Last updated on GMT


Related tags Pharmacology Parkinson

Mitsubishi Tanabe Pharma has agreed to pay $1.1bn (€943m) to acquire Parkinson’s disease focused formulation and drug-device developer Neuroderm Ltd.

Neuroderm’s lead product candidate – ND0612 – is a liquid formulation combining levodopa and carbidopa. The production – which is in Phase III trials in the US - is designed for continuous administration using specially developed, belt worn pump.

The Israel-based firm has a second Parkinson’s disease drug ND0701 (apomorphine) in development, as well as a transdermal CNS disease medication called ND0801 (nicotide and opipramol).

Related news

Related products

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Business Advice

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Related suppliers

Follow us


View more